Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Neurosci. 2011 Sep;121(9):485-9. doi: 10.3109/00207454.2011.582240. Epub 2011 Jun 15.

Determining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: a review.

Author information

  • 1Coastal Neurological Medical Group, Inc., La Jolla, California 92037, USA. deeesilver@aol.com

Abstract

BACKGROUND:

Bradykinesia has a significant impact on the lives of Parkinson's disease (PD) patients. Consequently, treating this symptom is of particular concern for patients and clinicians. A number of studies have documented the efficacy of rasagiline in reducing the severity of PD symptoms.

OBJECTIVE:

To summarize studies that specifically examined the impact of rasagiline on bradykinesia symptoms in PD patients across disease severity.

METHODS:

The EMBASE database was searched for relevant articles published between 2000 and November 2010.

RESULTS:

Three studies were identified that explicitly examined the effect of rasagiline on the bradykinesia subscale of the Unified Parkinson's Disease Rating Scale (UPDRS) motor examination. In each, 1 mg/day rasagiline significantly reduced bradykinesia scores in patients.

CONCLUSION:

As a monotherapy or an adjunctive therapy, rasagiline is an effective drug for reducing the severity of bradykinesia in PD patients.

PMID:
21671840
DOI:
10.3109/00207454.2011.582240
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center